By Counterforce Health Team in Kesimpta (ofatumumab) —

How to Get Kesimpta (Ofatumumab) Covered by UnitedHealthcare in Ohio: Complete ICD-10, HCPCS, and Prior Authorization Guide

Answer Box: Get Kesimpta Covered by UnitedHealthcare in Ohio

Kesimpta (ofatumumab) requires prior authorization from UnitedHealthcare OptumRx in Ohio, typically with step therapy requiring trials of preferred DMTs first. The fastest path: (1) Verify eligibility via UHC member portal, (2) Submit PA with MS diagnosis (new ICD-10 G35.A for RRMS effective Oct 2025), hepatitis B screening, and prior DMT failures, (3) Appeal denials within 180 days using Ohio's external review if needed. Standard approval takes 1-3 days; expedited reviews available for urgent cases.

First step today: Call UnitedHealthcare member services at the number on your insurance card to confirm formulary status and PA requirements for your specific plan.

Table of Contents

Coding Basics: Medical vs. Pharmacy Benefit

Kesimpta (ofatumumab) is covered under UnitedHealthcare's pharmacy benefit as a self-administered subcutaneous injection for relapsing forms of multiple sclerosis. This distinction is crucial for proper billing and approval.

Coverage at a Glance

Requirement Details Documentation Needed
Prior Authorization Required for all UHC plans MS diagnosis, hepatitis B screening, prior DMT failures
Formulary Status Specialty tier with step therapy Exception request if non-preferred
Benefit Type Pharmacy (self-administered) Avoid medical benefit billing
ICD-10 Code G35.A (RRMS) effective Oct 2025 Provider documentation of MS subtype
Appeals Deadline 180 days in Ohio Internal then external review available

Sources: UHC Prior Authorization Requirements, Ohio Department of Insurance

ICD-10 Mapping for Multiple Sclerosis

Critical Update: Starting October 1, 2025, the generic MS code G35 becomes obsolete. UnitedHealthcare will require specific MS subtype codes for prior authorization approval.

New Required ICD-10 Codes

Code Description When to Use
G35.A Relapsing-remitting multiple sclerosis Most Kesimpta patients
G35.C1 Active secondary progressive MS SPMS with recent activity
G35.C2 Non-active secondary progressive MS Stable SPMS
G35.D Multiple sclerosis, unspecified Only if subtype unclear

Documentation Requirements

Your neurologist must explicitly state the MS subtype in medical records. Key phrases that support proper coding:

  • "Patient has relapsing-remitting multiple sclerosis"
  • "Diagnosis: RRMS with recent relapse activity"
  • "Secondary progressive MS, currently active"
Tip: Request that your neurologist update your chart with specific MS subtype language before submitting your prior authorization to avoid delays.

Source: CMS FY2026 ICD-10-CM Guidelines

Product Coding: HCPCS, J-Codes, and NDCs

HCPCS J-Codes for Kesimpta

  • Primary: J3590 (unclassified biologics) or J3490
  • Alternative: J9302 (injection, ofatumumab, 10 mg) - typically for IV Arzerra but may be used

NDC Codes

  • 0078-1007-68 and 0078-1007-98 (Novartis Pharmaceuticals)

Billing Units and Dosage

  • Standard regimen: 20 mg subcutaneous at Weeks 0, 1, 2; then 20 mg monthly
  • Billing calculation: If using J9302 (10 mg per unit), bill 2 units per 20 mg dose
  • Pharmacy benefit: Use NDC codes for self-administered medication claims
Note: Avoid medical benefit billing unless supervised administration is documented. Most Kesimpta is self-administered at home.

Source: Daily Med FDA Label

Clean Prior Authorization Request

Required Documentation Checklist

Clinical Documentation:

  • MS diagnosis with ICD-10 G35.A (or appropriate subtype)
  • Neurologist prescription and clinical notes
  • Prior DMT trial history (typically 2+ agents for 3-6 months each)
  • Treatment failure/intolerance documentation

Safety Labs (Mandatory):

  • Hepatitis B panel: HBsAg (must be negative), anti-HBc, anti-HBs
  • Quantitative immunoglobulins
  • Complete blood count with differential
  • Comprehensive metabolic panel

Submission Process:

  1. Submit via UHC Provider Portal or call 866-889-8054
  2. Include all documentation in initial submission
  3. Request expedited review if clinically urgent
  4. Track status via portal or OptumRx at 1-800-711-4555

Source: UHC Provider Portal

Frequent Coding Pitfalls

Common Errors That Delay Approval

Problem Impact Solution
Using obsolete G35 code PA rejection after Oct 2025 Update to G35.A or specific subtype
Missing hepatitis B screening Automatic denial Complete HBsAg, anti-HBc, anti-HBs panel
Insufficient step therapy documentation Step therapy denial Document 2+ prior DMT failures with dates/outcomes
Wrong benefit type Claim rejection Ensure pharmacy benefit billing, not medical
Missing provider specialty PA delay Require neurologist prescription

Unit Conversion Mistakes

  • Error: Billing 1 unit for 20 mg dose when using J9302
  • Correction: Bill 2 units (J9302 = 10 mg per unit)
  • Best practice: Use NDC codes for pharmacy benefit to avoid unit confusion

Verification with UnitedHealthcare

Pre-Submission Verification Steps

  1. Check formulary status: Use UHC member portal or call member services
  2. Confirm PA requirements: Review current formulary document for your plan
  3. Verify provider network: Ensure prescribing neurologist is in-network
  4. Check prior authorizations: Review any existing approvals or denials

UnitedHealthcare Resources

  • Member Portal: Log in with insurance ID to check benefits
  • Provider Portal: For healthcare professionals to submit PAs
  • Member Services: Phone number on back of insurance card
  • OptumRx: 1-800-711-4555 for specialty pharmacy questions

Source: UHC Provider Resources

Quick Audit Checklist

Pre-Submission Review

Patient Information:

  • Correct member ID and group number
  • Current address and contact information
  • Primary care physician and neurologist listed

Clinical Documentation:

  • ICD-10 G35.A or appropriate MS subtype code
  • Neurologist prescription with clear rationale
  • Complete hepatitis B screening results (HBsAg negative)
  • Prior DMT trial documentation (minimum 2 agents)
  • Treatment failure/intolerance notes with dates

Coding Accuracy:

  • Correct NDC codes (0078-1007-68 or 0078-1007-98)
  • Appropriate HCPCS codes if needed
  • Pharmacy benefit designation confirmed
  • Unit calculations verified

Submission Details:

  • All required forms completed
  • Supporting documentation attached
  • Expedited review requested if urgent
  • Tracking number or confirmation received

Appeals Process in Ohio

If UnitedHealthcare denies your Kesimpta prior authorization, Ohio provides strong consumer protections through a structured appeals process.

Internal Appeals with UnitedHealthcare

  • Deadline: 180 days from denial notice
  • Process: Submit appeal via UHC Provider Portal or mail
  • Timeline: Standard review within 30 days; expedited within 72 hours
  • Required: Include denial letter, additional clinical documentation, medical necessity letter

Ohio External Review

After exhausting internal appeals, you can request an external review through an Independent Review Organization (IRO) at no cost.

Timeline:

  • Standard review: 30 days for IRO decision
  • Expedited review: 72 hours if delay could endanger health
  • Eligibility: Available for medical necessity denials

How to Request:

  1. File request within 180 days of final internal denial
  2. Submit to your health plan (they notify Ohio Department of Insurance)
  3. Provide all relevant medical records and documentation
Important: Even self-funded employer plans often provide external review options, though they may follow federal ERISA rules rather than Ohio state law.

Getting Help in Ohio

  • Ohio Department of Insurance Consumer Services: 1-800-686-1526
  • UHCAN Ohio (Universal Health Care Action Network): Nonprofit consumer assistance
  • External Review Request Form: Available on ODI website

Source: Ohio Department of Insurance

Counterforce Health: Streamlining Your Appeal Process

When facing a Kesimpta denial from UnitedHealthcare, Counterforce Health helps patients and clinicians turn insurance denials into targeted, evidence-backed appeals. The platform analyzes denial letters and plan policies to identify the specific denial basis—whether it's PA criteria, step therapy requirements, or "not medically necessary" determinations—then drafts point-by-point rebuttals aligned to UnitedHealthcare's own rules.

For Kesimpta appeals, Counterforce Health pulls the right evidence—FDA labeling, peer-reviewed studies on ofatumumab efficacy, and MS treatment guidelines—and weaves them into appeals with required clinical facts like ICD-10 codes, prior DMT failures, and hepatitis B screening results. This systematic approach helps ensure your appeal addresses UnitedHealthcare's specific concerns while meeting Ohio's procedural requirements for coverage determinations and external review.

FAQ

How long does UnitedHealthcare prior authorization take for Kesimpta in Ohio? Standard prior authorization decisions are typically made within 1-3 business days. Expedited reviews for urgent cases can be completed within 24-72 hours.

What if Kesimpta is non-formulary on my UnitedHealthcare plan? You can request a formulary exception by demonstrating medical necessity and providing documentation that preferred alternatives have failed or are contraindicated.

Can I request an expedited appeal if my Kesimpta is denied? Yes, if delaying treatment could seriously jeopardize your health. Both UnitedHealthcare internal appeals and Ohio external reviews offer expedited options.

Does step therapy apply if I tried DMTs outside of Ohio? Yes, prior DMT trials from any location count toward step therapy requirements, as long as you have proper documentation of the trials and outcomes.

What happens if I miss the 180-day appeal deadline? You may lose your right to internal and external appeals for that specific denial. However, you can resubmit a new prior authorization with additional documentation.

Do I need a neurologist to prescribe Kesimpta, or can my primary care doctor? UnitedHealthcare typically requires a neurologist or MS specialist to prescribe Kesimpta, as it's considered a specialty medication requiring specialized monitoring.

How much will Kesimpta cost with UnitedHealthcare coverage? Costs vary by plan, but specialty tier medications typically have higher copays. Check with Novartis for patient assistance programs and copay cards that may reduce out-of-pocket costs.

Can I use Ohio's external review for step therapy denials? Yes, if the step therapy requirement involves medical judgment about what treatments are appropriate for your condition, it may qualify for external review.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance company for the most current requirements and procedures. Insurance policies and state regulations may change, and individual circumstances vary.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.